ALE1 III clinical trials

A Randomised, Placebo-Controlled, Double-Blind, Single-Ascending Dose and Multiple-Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered ALE1 With or Without Food in Healthy Adult Participants and Adult Patients With Hypophosphatasia

This study is testing a new medicine, ALE1, for a condition called Hypophosphatasia (HPP). We are looking at its safety and how the body handles it in healthy people and those with HPP, starting with small doses.